Somituximab (Mirvetuximab) Targeted/Immune Drug Properties

Mirvetuximab (Mirvetuximab) is an antibody-drug conjugate (ADC) in the drug classification. Its essence is a compound biological drug that integrates targeted therapy and chemotherapeutic activity. Different from traditional monoclonal antibodies, somituximab not only has the role of identifying cancer cells, but also achieves the dual mechanism of selectively releasing toxins by carrying a potent cytotoxic load. Its treatment logic is a typical targeted precision therapy rather than immunotherapy in a simple sense, so it is usually classified as a targeted drug in clinical applications.

From a mechanism of action point of view, the target of somituximab is folate receptor α (FRα), which is highly expressed in some ovarian cancers, fallopian tube cancers and peritoneal cancers, making it a very suitable molecular target for ADC drugs. Somituximab specifically binds to FRα on the tumor surface through the antibody moiety, and releases the toxin DM4 within the cells, causing microtubule destruction and apoptosis in tumor cells. This mode of action is highly targeted and reduces the widespread damage that traditional chemotherapy causes throughout the body.

Although its core mechanism is targeted therapy, because the antibody structure is derived from immunology, some patients may experience mild immune-related or infusion reactions. However, such reactions do not classify it as an immune checkpoint inhibitor or cellular immunity drug. Compared withPD-1, PD-L1 or CTLA-4 drugs, somituximab does not attack tumors by regulating the immune system, but relies on the cytotoxic effect released by the antibody carrier to exert its therapeutic effect.

In clinical use, somituximab usually needs to screen patients based onFRα expression levels. Only people who reach a certain expression ratio can benefit from it. This is its typical companion diagnostic attribute and an important part of modern precision medicine. Compared with traditional chemotherapy, it has advantages in safety and targeting, and compared with simple targeted tyrosine kinase inhibitors, its ADC structure gives it stronger cell killing ability.

Reference materials:https://www.elahere.com/